Guangdong VTR Bio-Tech Co., Ltd. (SHE:300381)
China · Delayed Price · Currency is CNY 6.41
-0.28 (-4.19%)
Jun 2, 2026, 3:04 PM CST
Guangdong VTR Bio-Tech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 834.3 | 824.06 | 821.47 | 790.19 | 1,149 | 1,838 |
Other Revenue | 8.2 | 8.2 | 4.73 | 5.83 | 24.81 | 53.95 |
| 842.5 | 832.26 | 826.2 | 796.02 | 1,174 | 1,892 | |
Revenue Growth (YoY) | 1.54% | 0.73% | 3.79% | -32.20% | -37.95% | -1.18% |
Cost of Revenue | 466.19 | 466.02 | 460.33 | 459.12 | 816.91 | 1,217 |
Gross Profit | 376.31 | 366.24 | 365.87 | 336.9 | 357.1 | 675.22 |
Selling, General & Admin | 273.46 | 272.43 | 249.87 | 273.98 | 329.93 | 465.35 |
Research & Development | 105.43 | 104.95 | 109.32 | 99.82 | 99.87 | 129.78 |
Other Operating Expenses | 6.75 | 7.06 | 2.85 | 8.72 | 16.36 | 24.61 |
Operating Expenses | 386.14 | 384.95 | 363.48 | 365.74 | 445.99 | 654.69 |
Operating Income | -9.83 | -18.72 | 2.4 | -28.83 | -88.89 | 20.53 |
Interest Expense | -0.73 | -0.73 | -6.51 | -2.83 | -19.76 | -34.4 |
Interest & Investment Income | 14.22 | 14.1 | 15.5 | 27.89 | 175.88 | 1.78 |
Currency Exchange Gain (Loss) | -5.52 | -5.52 | 2.66 | 0.65 | 15.31 | -9.01 |
Other Non Operating Income (Expenses) | 1.19 | -0.67 | -0.87 | -0.24 | -1.87 | -2.65 |
EBT Excluding Unusual Items | -0.67 | -11.54 | 13.18 | -3.35 | 80.67 | -23.76 |
Impairment of Goodwill | - | - | - | - | - | -80.83 |
Gain (Loss) on Sale of Investments | -2.54 | -4.98 | 9.36 | 5.38 | 8.89 | -2.28 |
Gain (Loss) on Sale of Assets | -0.17 | -0.1 | 3.01 | 0.05 | -0.06 | -0.23 |
Asset Writedown | -5.87 | -5.87 | -7.87 | -12.95 | -0.43 | -1.64 |
Other Unusual Items | 6.06 | 6.06 | 14.09 | 12.15 | 16 | 20.02 |
Pretax Income | -3.19 | -16.43 | 31.78 | 1.28 | 105.07 | -88.72 |
Income Tax Expense | 3.05 | 2.11 | -0.17 | 0.13 | 67.55 | -3.29 |
Earnings From Continuing Operations | -6.24 | -18.54 | 31.95 | 1.15 | 37.52 | -85.43 |
Minority Interest in Earnings | -1.92 | -1.24 | -0.86 | -11.9 | -19.29 | -33.48 |
Net Income | -8.16 | -19.78 | 31.09 | -10.75 | 18.23 | -118.91 |
Net Income to Common | -8.16 | -19.78 | 31.09 | -10.75 | 18.23 | -118.91 |
Shares Outstanding (Basic) | 490 | 491 | 490 | 491 | 490 | 490 |
Shares Outstanding (Diluted) | 490 | 491 | 490 | 491 | 490 | 490 |
Shares Change (YoY) | -0.11% | 0.08% | -0.09% | 0.15% | -0.01% | 4.75% |
EPS (Basic) | -0.02 | -0.04 | 0.06 | -0.02 | 0.04 | -0.24 |
EPS (Diluted) | -0.02 | -0.04 | 0.06 | -0.02 | 0.04 | -0.24 |
Free Cash Flow | -119.46 | -156.16 | -308.2 | -239.77 | 51.99 | 53.95 |
Free Cash Flow Per Share | -0.24 | -0.32 | -0.63 | -0.49 | 0.11 | 0.11 |
Dividend Per Share | 0.050 | 0.050 | 0.100 | 0.060 | 0.100 | 0.100 |
Dividend Growth | -50.00% | -50.00% | 66.67% | -40.00% | - | 42.86% |
Gross Margin | 44.67% | 44.01% | 44.28% | 42.32% | 30.42% | 35.69% |
Operating Margin | -1.17% | -2.25% | 0.29% | -3.62% | -7.57% | 1.08% |
Profit Margin | -0.97% | -2.38% | 3.76% | -1.35% | 1.55% | -6.28% |
Free Cash Flow Margin | -14.18% | -18.76% | -37.30% | -30.12% | 4.43% | 2.85% |
EBITDA | 121.43 | 108.92 | 115.54 | 82.84 | 48.96 | 188.39 |
EBITDA Margin | 14.41% | 13.09% | 13.98% | 10.41% | 4.17% | 9.96% |
D&A For EBITDA | 131.26 | 127.63 | 113.14 | 111.68 | 137.85 | 167.86 |
EBIT | -9.83 | -18.72 | 2.4 | -28.83 | -88.89 | 20.53 |
EBIT Margin | -1.17% | -2.25% | 0.29% | -3.62% | -7.57% | 1.08% |
Effective Tax Rate | - | - | - | 9.92% | 64.29% | - |
Revenue as Reported | 832.26 | 832.26 | 826.2 | 796.02 | 1,174 | 1,892 |